Ignite Creation Date:
2024-05-05 @ 4:52 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00335751
Status:
COMPLETED
Last Update Posted:
2020-07-31
First Post:
2006-06-08
Brief Title:
PET Scan Combined With CT Scan in Evaluating Treatment Response in Patients Undergoing Treatment for Bone Cancer or Soft Tissue Sarcoma
Sponsor:
Jonsson Comprehensive Cancer Center
Organization:
Jonsson Comprehensive Cancer Center
Study Overview
Official Title:
Glucose Metabolic Response by PETCT to Sarcoma Treatments
Status:
COMPLETED
Status Verified Date:
2016-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Diagnostic procedures such as PET scan and CT scan may help doctors determine the extent of cancer and predict a patients response to treatment and help plan the best treatment
PURPOSE This clinical trial is studying how well PET scan combined with CT scan evaluates treatment response in patients undergoing treatment for bone cancer or soft tissue sarcoma
PURPOSE This clinical trial is studying how well PET scan combined with CT scan evaluates treatment response in patients undergoing treatment for bone cancer or soft tissue sarcoma
Detailed Description:
OBJECTIVES
Determine whether an FDA-approved device that combines fludeoxyglucose 18F positron-emission tomography FDG-PET and CT scanning FDG-PETCT can accurately locate and determine the extent of disease in patients who are undergoing treatment for bone or soft tissue sarcoma
Determine whether FDG-PETCT scanning is effective in evaluating the response of sarcoma to treatment
Determine whether the new FDG-PETCT device improves the ability to evaluate treatment response early and accurately
Correlate changes in glucose metabolic activity early and late after treatment with overall and progression-free survival
Correlate changes in glucose metabolic activity early and late after treatment with degree of tumor necrosis at the time of surgery
OUTLINE This is a prospective pilot study Patients are stratified according to disease high-grade soft tissue sarcoma vs low-grade soft tissue sarcoma vs osteosarcoma
Patients undergo fludeoxyglucose 18F positron-emission tomography FDG-PETCT scanning at baseline and then within 2 weeks and 12 weeks after the start of treatment total of 3 scans
PROJECTED ACCRUAL A total of 120 patients will be accrued for this study
Determine whether an FDA-approved device that combines fludeoxyglucose 18F positron-emission tomography FDG-PET and CT scanning FDG-PETCT can accurately locate and determine the extent of disease in patients who are undergoing treatment for bone or soft tissue sarcoma
Determine whether FDG-PETCT scanning is effective in evaluating the response of sarcoma to treatment
Determine whether the new FDG-PETCT device improves the ability to evaluate treatment response early and accurately
Correlate changes in glucose metabolic activity early and late after treatment with overall and progression-free survival
Correlate changes in glucose metabolic activity early and late after treatment with degree of tumor necrosis at the time of surgery
OUTLINE This is a prospective pilot study Patients are stratified according to disease high-grade soft tissue sarcoma vs low-grade soft tissue sarcoma vs osteosarcoma
Patients undergo fludeoxyglucose 18F positron-emission tomography FDG-PETCT scanning at baseline and then within 2 weeks and 12 weeks after the start of treatment total of 3 scans
PROJECTED ACCRUAL A total of 120 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| UCLA-0508095-01 | None | None | None |